Lipocine Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lipocine Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
$77Sales grew 295% in 3 years; of every extra $100 of sales, $77 became extra profit.
Higher than 77% of Healthcare companies in United States.
Asset Productivity Ratio
+295% / -55%In 3 years sales changed by +295% while total assets changed by -55%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Lipocine Inc. made a loss over the last year. Lipocine Inc. owes $0.09 for every $1 it owns. Lipocine Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLipocine Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.55The share price is 0.55 times Lipocine Inc.'s book value per share, lower than 90% of Healthcare companies in United States.
Market cap
$12 MThe total market value of all of Lipocine Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$22 MWhat Lipocine Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.64Net worth divided by the number of shares. The share price of $1.46 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-60.9%Lipocine Inc. lost 60.9% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
Owes vs Owns
0.09×Lipocine Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Dividend yield
NoneLipocine Inc. does not currently pay a dividend.
Revenue growth
-82%Revenue fell 82% in the year to Dec 2025, and grew 58% a year on average over 3 years.
Profit growth
LossLipocine Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-487.1%Lipocine Inc. lost $487 for every $100 of revenue.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lipocine Inc.: $12 M ÷ $22 M (30 Jun 2026) = 0.6.
What is Lipocine Inc.'s return on equity?
Lipocine Inc. lost 60.9% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
How much does Lipocine Inc. owe compared with what it owns?
Lipocine Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Does Lipocine Inc. pay a dividend?
No. Lipocine Inc. does not currently pay a dividend.
Is Lipocine Inc.'s revenue growing?
Revenue fell 82% in the year to Dec 2025, and grew 58% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.